In focus channel feed

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

Last year
R&D
Coronavirus

Bank­ing on hope, swayed by hype? Hy­drox­y­chloro­quine in the time of Covid-19

Last year
FDA+
Coronavirus

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

Last year
R&D
Coronavirus

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

Last year
R&D
Coronavirus

‘If grippe con­demns, the sec­ondary in­fec­tions ex­e­cute’: What the coro­n­avirus pan­dem­ic means for the field of an­tibi­otics

Last year
Coronavirus

In­vest­ing in the time of coro­n­avirus: the good, the bad and the hope­ful, as biotech VC firms close funds worth $3B

Last year
Financing

‘It’s like the tor­toise and the hare’: A pan­dem­ic puts Sanofi’s $600M bet to the test

Last year
R&D
Coronavirus

'Dra­mat­ic times': How did an $8B surge in NIH grants over five years change re­search on the ground (if at all)?

Last year
Discovery

A 9/11-era Om­a­ha fa­cil­i­ty, an old Ebo­la drug, and the ubiq­ui­tous Dr. Fau­ci: In­side the first US nov­el coro­n­avirus tri­al

Last year
R&D
Coronavirus

For two decades, a new vac­cine tech­nol­o­gy has been slow­ly ap­proach­ing prime time. Now, can it stop a pan­dem­ic?

Last year
R&D

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on Covid-19

Last year
R&D

Carl June on CRISPR, CAR–T and how the Viet­nam War dropped him in­to med­i­cine

Last year
People
R&D

Can we make the an­tibi­ot­ic mar­ket great again?

Last year
R&D

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

Last year
R&D
Cell/Gene Tx

#JPM20: Af­ter a year of NASH col­laps­es, all eyes on two biotechs

Last year
R&D

Over a decade in­to the mile­stone boom, it's time to ask. Just how of­ten do they re­al­ly pay off?

Last year
Deals

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

Last year
China

Path to the top: What kind of ex­pe­ri­ence does it take to get tapped for the helm of a biotech?

3 years ago
People

Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017

4 years ago
Discovery
First page Previous page 12